U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07169279) titled 'Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)' on June 23.
Brief Summary: This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants < 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children < 3 years old with ACH at the selected dose.
Study Start Date: Oct., 2025
Stud...